QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
Open-Label Phase 1 Study of PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
Sponsor: ImmunityBio, Inc.
A PHASE1 clinical study on Locally Advanced Solid Tumor and Metastatic Cancer, this trial is ongoing. The trial is conducted by ImmunityBio, Inc. and has accumulated 12 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Nov 2025 — Mar 2026 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 7 earlier versions
-
Oct 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE1
-
Apr 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE1
-
Apr 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — Oct 2020 [monthly]
Recruiting PHASE1
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ImmunityBio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .